LDS/Medical Tests/Dopamine D2L receptor (DRD2L) Antibody, IgG

Dopamine D2L receptor (DRD2L) Antibody, IgG

The Dopamine D2L receptor (DRD2L) Antibody, IgG assay measures the antibody titer against the neuronal antigen Dopamine D2L and compares this measurement to a normal control titer against Dopamine D2L. An article in The Journal of Immunology in 2013 (Cox et al) showed that when the genes for the Sydenham chorea-derived human monoclonal antibody are expressed in transgenic mice, the antibody is expressed by B cells and is produced in the serum of the mice; once the blood brain barrier is broken, the antibody targets the substantia nigra and ventral tegumental areas in the brain, which are in the basal ganglia where the antibodies are targeted in Sydenham chorea. This antibody also targeted primarily the D2 receptor. There is little doubt that the anti-D2 receptor activity must increase the dopamine in Sydenham chorea and PANDAS with th choreiform movements. Supportive human studies and all of the data collected from animal model experiments which mimic Sydenham chorea show inability to write, draw or hold objects in the hand.

The two types of anti-neuronal human antibodies against the dopamine receptors which were studied were found to induce increased dopamine release and also alter the receptors to cause an increase in their activity and sensitivity to dopamine. Thus, these antibodies are likely important in the pathogenesis of neuropsychiatric diseases. The Dopamine 2L (DRD2L) Antibody, IgG is one of the five tests which comprise The Cunningham Panel™ of Tests.

The Cunningham Panel™ tests measure human serum Immunoglobulin G (IgG) levels by Enzyme-Linked ImmunoSorbent Assay (ELISA) directed against: Dopamine D1 Receptor (DRD1), Dopamine D2L Receptor (DRD2L), Lysoganglioside-GM1 (LYSO-GM1) and Tubulin (TUB). ELISA results are determined by measuring the colorimetric intensity at a specific wavelength which is directly proportional to the amount of antibody in the sample. The fifth assay of this panel measures the specific activity of calcium/calmodulin-dependent protein kinase II (CaM KII) induced by the patient’s serum in cultured human neuronal cell lines compared to controls. This panel measures the level of these antibodies, and the ability of the patient’s sera to stimulate CaM KII at a single point in time. The Cunningham Panel™ of Tests is a proprietary test panel exclusively offered by Moleculera Labs. For more information please see .

  • As an aid in diagnosis and management Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcus (PANDAS)
  • As an aid in diagnosis and management of pediatric acute-onset neuropsychiatric syndrome (PANS) 
  • As an aid in diagnosis and management of Sydenham's chorea (post Rheumatic Fever)
  • As an aid in diagnosis and management of Autism spectrum disorder, specifically regressive autism, that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of treatment resistant psychiatric illnesses and symptoms that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of chronic depression that could have an anti-neuronal autoimmune basis 
  • As an aid in diagnosis and management of anxiety disorders that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of ADHD/ADD that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of OCD that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of Tourette’s Syndrome that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of bipolar depression that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of new onset enuresis/incontinence that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of rage disorder that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of ODD that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of behavioral regression that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of cognitive decline that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of sensory abnormalities that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of dysgraphia that could have an anti-neuronal autoimmune basis
  • As an aid in diagnosis and management of anorexia that could have an anti-neuronal autoimmune basis

If any one (1) or more of these five (5) assay values is elevated, it may indicate a clinically significant autoimmune neurological condition.

Note: It is important to note that the degree of elevation in assay values may not necessarily correlate with degree of symptom severity. Any value above normal ranges may correlate with symptomatology. Results may vary depending on the patient’s condition and status, whether they are on immunosuppressive agents, corticosteroids or other immune modulatory therapy, and the length of time post treatment.

Reference ranges based on pediatric control group:

 

  Anti-Dopamine Receptor D1 (titer) Anti-Dopamine Receptor D2L (titer) Anti-Lysoganglioside GM1 (titer) Anti-Tubulin (titer) CaM Kinase II (% of baseline)
Normal Ranges 500 - 2,000 2,000 - 8,000 80 - 320 250 - 1,000 53 - 130
Normal Mean 1,056 6,000 147 609 95

 

Enzyme-Linked Immunosorbent Assays (ELISAs)

Serum (Red top tube).

4-5 mL serum collected in red-top glass tube with no additives or gel barrier. Ship on two fully frozen 8-ounce ice packs, overnight only Monday-Thursday. Do not ship on Friday or before a US holiday.

Stability

  • Frozen: 1 year
IgG and IgM titer measurement for any known or suspected past, recent, or current infection, testing for general metabolic and genetic markers such as GAD 65, MTHFR; testing for IgG and/or IgM to EBV, CMV, HHV6 and other viruses in the Herpes family, Lyme Disease IgG, IgM; Babesisia and Bartonella antibodies, ASO titer, DNaseB titers, Group A strep blood cultures.
Approximately 2–3 weeks
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  •  J Child Adolesc Psychopharmacol. 2015;25(1):76-85. [PMID: 25658702]
  •  J Child Adolesc Psychopharmacol. 2015;25(1):3-13. [PMID: 25325534]
  •  Nature Medicine. 2003;9(7):914-920. [PMID: 12819778]
  •  PLoS One. 2013;8(9):e73516. [PMID: 24073196]
  •  Acta Physiol (Oxf). 2016;216(1):90-100. [PMID: 26454143]
  •  Immunology. 2007;178:7412-7421. [PMID: 17513792]